{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:26:31Z","timestamp":1790011591690,"version":"4.0.1"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T00:00:00Z","timestamp":1500422400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Indiana University Health\u2013Indiana University School of Medicine Strategic Research Initiative"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s00125-017-4370-8","type":"journal-article","created":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T11:29:37Z","timestamp":1500463777000},"page":"1862-1872","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":197,"title":["SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials"],"prefix":"10.1007","volume":"60","author":[{"given":"Huilin","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weilong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suodi","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqing","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,19]]},"reference":[{"key":"4370_CR1","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.2337\/dc10-0666","volume":"33","author":"E Giovannucci","year":"2010","unstructured":"Giovannucci E, Harlan DM, Archer MC et al (2010) Diabetes and cancer: a consensus report. Diabetes Care 33:1674\u20131685","journal-title":"Diabetes Care"},{"key":"4370_CR2","doi-asserted-by":"crossref","first-page":"i3832","DOI":"10.1136\/bmj.i3832","volume":"354","author":"S Mayor","year":"2016","unstructured":"Mayor S (2016) Cancer risk is higher in years before and shortly after type 2 diabetes diagnosis, study shows. BMJ 354:i3832","journal-title":"BMJ"},{"key":"4370_CR3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nrclinonc.2016.120","volume":"14","author":"AJ Klil-Drori","year":"2017","unstructured":"Klil-Drori AJ, Azoulay L, Pollak MN (2017) Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing? Nat Rev Clin Oncol 14:85\u201399","journal-title":"Nat Rev Clin Oncol"},{"key":"4370_CR4","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1177\/1479164114549553","volume":"11","author":"SZ Lutz","year":"2014","unstructured":"Lutz SZ, Staiger H, Fritsche A, Haring HU (2014) Antihyperglycaemic therapies and cancer risk. Diab Vasc Dis Res 11:371\u2013389","journal-title":"Diab Vasc Dis Res"},{"key":"4370_CR5","doi-asserted-by":"crossref","first-page":"i1541","DOI":"10.1136\/bmj.i1541","volume":"352","author":"M Tuccori","year":"2016","unstructured":"Tuccori M, Filion KB, Yin H, Yu OH, Platt RW, Azoulay L (2016) Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ 352:i1541","journal-title":"BMJ"},{"key":"4370_CR6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2015.7996","volume":"314","author":"JD Lewis","year":"2015","unstructured":"Lewis JD, Habel LA, Quesenberry CP et al (2015) Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA 314:265\u2013277","journal-title":"JAMA"},{"key":"4370_CR7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/jdi.12214","volume":"5","author":"Y Fujita","year":"2014","unstructured":"Fujita Y, Inagaki N (2014) Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: clinical data and mechanism of action. J Diabetes Invest 5:265\u2013275","journal-title":"J Diabetes Invest"},{"key":"4370_CR8","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrendo.2011.243","volume":"8","author":"E Ferrannini","year":"2012","unstructured":"Ferrannini E, Solini A (2012) SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 8:495\u2013502","journal-title":"Nat Rev Endocrinol"},{"key":"4370_CR9","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1053\/j.ajkd.2008.12.031","volume":"53","author":"O Marsenic","year":"2009","unstructured":"Marsenic O (2009) Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis 53:875\u2013883","journal-title":"Am J Kidney Dis"},{"key":"4370_CR10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/dom.12244","volume":"16","author":"M Monami","year":"2014","unstructured":"Monami M, Nardini C, Mannucci E (2014) Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 16:457\u2013466","journal-title":"Diabetes Obes Metab"},{"key":"4370_CR11","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","volume":"38","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB et al (2015) Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38:140\u2013149","journal-title":"Diabetes Care"},{"key":"4370_CR12","unstructured":"US Food and Drug Administration (2011) FDA briefing document, NDA 202293 Dapagliflozin tablets, 5 and 10 mg. Advisory Committee Meeting. Available from \nhttp:\/\/www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/endocrinologicandmetabolicdrugsadvisorycommittee\/ucm262994.pdf\n\n. Accessed 25 Aug 2016"},{"key":"4370_CR13","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s13300-015-0128-9","volume":"6","author":"A Ptaszynska","year":"2015","unstructured":"Ptaszynska A, Cohen SM, Messing EM, Reilly TP, Johnsson E, Johnsson K (2015) Assessing bladder cancer risk in type 2 diabetes clinical trials: the dapagliflozin drug development program as a 'case study'. Diabetes Ther 6:357\u2013375","journal-title":"Diabetes Ther"},{"key":"4370_CR14","first-page":"719578","volume":"2014","author":"HW Lin","year":"2014","unstructured":"Lin HW, Tseng CH (2014) A review on the relationship between SGLT2 inhibitors and cancer. Int J Endocrinol 2014:719578","journal-title":"Int J Endocrinol"},{"key":"4370_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cbi.2014.09.018","volume":"224","author":"S Jonghe De","year":"2014","unstructured":"De Jonghe S, Proctor J, Vinken P et al (2014) Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin. Chem Biol Interact 224:1\u201312","journal-title":"Chem Biol Interact"},{"key":"4370_CR16","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1021\/tx500380t","volume":"28","author":"ME Taub","year":"2015","unstructured":"Taub ME, Ludwig-Schwellinger E, Ishiguro N et al (2015) Sex-, species-, and tissue-specific metabolism of empagliflozin in male mouse kidney forms an unstable hemiacetal metabolite (M466\/2) that degrades to 4-hydroxycrotonaldehyde, a reactive and cytotoxic species. Chem Res Toxicol 28:103\u2013115","journal-title":"Chem Res Toxicol"},{"key":"4370_CR17","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of healthcare interventions: checklist and explanations. Ann Intern Med 162:777\u2013784","journal-title":"Ann Intern Med"},{"key":"4370_CR18","unstructured":"Higgins JPT, Altman DG, Sterne AC (2011) Chapter 8: assessing risk of bias in included studies. In: Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions 5.1.0. [updated March 2011]. The Cochrane Collaboration. Available from \nhttp:\/\/handbook.Cochrane.org\/chapter_8\/8_assessing_risk_of_bias_in_included_studies.htm\n\n. Accessed 25 Aug 2016"},{"key":"4370_CR19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/sim.2528","volume":"26","author":"MJ Bradburn","year":"2007","unstructured":"Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A (2007) Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 26:53\u201377","journal-title":"Stat Med"},{"key":"4370_CR20","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539\u20131558","journal-title":"Stat Med"},{"key":"4370_CR21","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117\u20132128","journal-title":"N Engl J Med"},{"key":"4370_CR22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jrsm.1045","volume":"3","author":"IR White","year":"2012","unstructured":"White IR, Barrett JK, Jackson D, Higgins JP (2012) Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods 3:111\u2013125","journal-title":"Res Synth Methods"},{"key":"4370_CR23","doi-asserted-by":"crossref","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","volume":"8","author":"A Chaimani","year":"2013","unstructured":"Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G (2013) Graphical tools for network meta-analysis in STATA. PLoS One 8:e76654","journal-title":"PLoS One"},{"key":"4370_CR24","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/ajg.2008.22","volume":"104","author":"F Keus","year":"2009","unstructured":"Keus F, Wetterslev J, Gluud C, Gooszen HG, van Laarhoven CJ (2009) Robustness assessments are needed to reduce bias in meta-analyses that include zero-event randomized trials. Am J Gastroenterol 104:546\u2013551","journal-title":"Am J Gastroenterol"},{"key":"4370_CR25","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1037","volume":"3","author":"G Salanti","year":"2012","unstructured":"Salanti G (2012) Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods 3:80\u201397","journal-title":"Res Synth Methods"},{"key":"4370_CR26","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/ije\/dys041","volume":"41","author":"RM Turner","year":"2012","unstructured":"Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP (2012) Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. Int J Epidemiol 41:818\u2013827","journal-title":"Int J Epidemiol"},{"key":"4370_CR27","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/ije\/dys222","volume":"42","author":"AA Veroniki","year":"2013","unstructured":"Veroniki AA, Vasiliadis HS, Higgins JP, Salanti G (2013) Evaluation of inconsistency in networks of interventions. Int J Epidemiol 42:332\u2013345","journal-title":"Int J Epidemiol"},{"key":"4370_CR28","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","volume":"3","author":"JP Higgins","year":"2012","unstructured":"Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR (2012) Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 3:98\u2013110","journal-title":"Res Synth Methods"},{"key":"4370_CR29","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/jrsm.57","volume":"3","author":"A Chaimani","year":"2012","unstructured":"Chaimani A, Salanti G (2012) Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. Res Synth Methods 3:161\u2013176","journal-title":"Res Synth Methods"},{"key":"4370_CR30","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/dom.12054","volume":"15","author":"K Stenlof","year":"2013","unstructured":"Stenlof K, Cefalu WT, Kim KA et al (2013) Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 15:372\u2013382","journal-title":"Diabetes Obes Metab"},{"key":"4370_CR31","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/ijcp.12322","volume":"67","author":"JP Wilding","year":"2013","unstructured":"Wilding JP, Charpentier G, Hollander P et al (2013) Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 67:1267\u20131282","journal-title":"Int J Clin Pract"},{"key":"4370_CR32","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1007\/s00125-013-3039-1","volume":"56","author":"FJ Lavalle-Gonz\u00e1lez","year":"2013","unstructured":"Lavalle-Gonz\u00e1lez FJ, Januszewicz A, Davidson J et al (2013) Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 56:2582\u20132592","journal-title":"Diabetologia"},{"key":"4370_CR33","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.2337\/dc12-2491","volume":"36","author":"G Schernthaner","year":"2013","unstructured":"Schernthaner G, Gross JL, Rosenstock J et al (2013) Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 36:2508\u20132515","journal-title":"Diabetes Care"},{"key":"4370_CR34","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/dom.12348","volume":"16","author":"JF Yale","year":"2014","unstructured":"Yale JF, Bakris G, Cariou B et al (2014) Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab 16:1016\u20131027","journal-title":"Diabetes Obes Metab"},{"key":"4370_CR35","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/dom.12273","volume":"16","author":"T Forst","year":"2014","unstructured":"Forst T, Guthrie R, Goldenberg R et al (2014) Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab 16:467\u2013477","journal-title":"Diabetes Obes Metab"},{"key":"4370_CR36","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2337\/dc13-2762","volume":"38","author":"LA Leiter","year":"2015","unstructured":"Leiter LA, Yoon KH, Arias P et al (2015) Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care 38:355\u2013364","journal-title":"Diabetes Care"},{"key":"4370_CR37","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/dom.12428","volume":"17","author":"B Bode","year":"2015","unstructured":"Bode B, Stenlof K, Harris S et al (2015) Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes Obes Metab 17:294\u2013303","journal-title":"Diabetes Obes Metab"},{"key":"4370_CR38","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/jdi.12266","volume":"6","author":"N Inagaki","year":"2015","unstructured":"Inagaki N, Kondo K, Yoshinari T, Kuki H (2015) Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: a 52-week open-label study. J Diabetes Investig 6:210\u2013218","journal-title":"J Diabetes Investig"},{"key":"4370_CR39","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2337\/dc15-1736","volume":"39","author":"J Rosenstock","year":"2016","unstructured":"Rosenstock J, Chuck L, Gonzalez-Ortiz M et al (2016) Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-naive type 2 diabetes. Diabetes Care 39:353\u2013362","journal-title":"Diabetes Care"},{"key":"4370_CR40","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.2337\/dc11-0606","volume":"34","author":"MA Nauck","year":"2011","unstructured":"Nauck MA, Del Prato S, Meier JJ et al (2011) Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 34:2015\u20132022","journal-title":"Diabetes Care"},{"key":"4370_CR41","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1463-1326.2011.01434.x","volume":"13","author":"K Strojek","year":"2011","unstructured":"Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S (2011) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 13:928\u2013938","journal-title":"Diabetes Obes Metab"},{"key":"4370_CR42","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1742-1241.2012.02911.x","volume":"66","author":"RR Henry","year":"2012","unstructured":"Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF (2012) Dapagliflozin, metformin XR, or both: Initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 66:446\u2013456","journal-title":"Int J Clin Pract"},{"key":"4370_CR43","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2337\/dc11-1693","volume":"35","author":"J Rosenstock","year":"2012","unstructured":"Rosenstock J, Vico M, Wei L, Salsali A, List JF (2012) Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 35:1473\u20131478","journal-title":"Diabetes Care"},{"key":"4370_CR44","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1463-1326.2012.01659.x","volume":"14","author":"CJ Bailey","year":"2012","unstructured":"Bailey CJ, Iqbal N, T'Joen C, List JF (2012) Dapagliflozin monotherapy in drug-naive patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab 14:951\u2013959","journal-title":"Diabetes Obes Metab"},{"key":"4370_CR45","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1741-7015-11-43","volume":"11","author":"CJ Bailey","year":"2013","unstructured":"Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF (2013) Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med 11:43","journal-title":"BMC Med"},{"key":"4370_CR46","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","volume":"85","author":"DE Kohan","year":"2014","unstructured":"Kohan DE, Fioretto P, Tang W, List JF (2014) Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85:962\u2013971","journal-title":"Kidney Int"},{"key":"4370_CR47","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/dom.12187","volume":"16","author":"JP Wilding","year":"2014","unstructured":"Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S (2014) Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab 16:124\u2013136","journal-title":"Diabetes Obes Metab"},{"key":"4370_CR48","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/dom.12189","volume":"16","author":"J Bolinder","year":"2014","unstructured":"Bolinder J, Ljunggren O, Johansson L et al (2014) Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 16:159\u2013169","journal-title":"Diabetes Obes Metab"},{"key":"4370_CR49","doi-asserted-by":"crossref","first-page":"740","DOI":"10.2337\/dc13-0467","volume":"37","author":"SA Jabbour","year":"2014","unstructured":"Jabbour SA, Hardy E, Sugg J, Parikh S (2014) Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care 37:740\u2013750","journal-title":"Diabetes Care"},{"key":"4370_CR50","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/jgs.12881","volume":"62","author":"LA Leiter","year":"2014","unstructured":"Leiter LA, Cefalu WT, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ (2014) Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. J Am Geriatr Soc 62:1252\u20131262","journal-title":"J Am Geriatr Soc"},{"key":"4370_CR51","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.clinthera.2013.11.002","volume":"36","author":"L Ji","year":"2014","unstructured":"Ji L, Ma J, Li H et al (2014) Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. Clin Ther 36:84\u2013100.e109","journal-title":"Clin Ther"},{"key":"4370_CR52","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/dom.12325","volume":"16","author":"K Kaku","year":"2014","unstructured":"Kaku K, Kiyosue A, Inoue S et al (2014) Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise. Diabetes Obes Metab 16:1102\u20131110","journal-title":"Diabetes Obes Metab"},{"key":"4370_CR53","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/dme.12624","volume":"32","author":"CJ Bailey","year":"2015","unstructured":"Bailey CJ, Morales Villegas EC, Woo V, Tang W, Ptaszynska A, List JF (2015) Efficacy and safety of dapagliflozin monotherapy in people with type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial. Diabet Med 32:531\u2013541","journal-title":"Diabet Med"},{"key":"4370_CR54","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.2337\/dc14-0315","volume":"38","author":"WT Cefalu","year":"2015","unstructured":"Cefalu WT, Leiter LA, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ (2015) Dapagliflozin's effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. Diabetes Care 38:1218\u20131227","journal-title":"Diabetes Care"},{"key":"4370_CR55","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/dom.12543","volume":"17","author":"S Matthaei","year":"2015","unstructured":"Matthaei S, Bowering K, Rohwedder K, Sugg J, Parikh S, Johnsson E (2015) Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes. Diabetes Obes Metab 17:1075\u20131084","journal-title":"Diabetes Obes Metab"},{"key":"4370_CR56","doi-asserted-by":"crossref","first-page":"376","DOI":"10.2337\/dc14-1142","volume":"38","author":"J Rosenstock","year":"2015","unstructured":"Rosenstock J, Hansen L, Zee P et al (2015) Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care 38:376\u2013383","journal-title":"Diabetes Care"},{"key":"4370_CR57","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.2337\/dc15-0779","volume":"38","author":"C Mathieu","year":"2015","unstructured":"Mathieu C, Ranetti AE, Li D et al (2015) A randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes. Diabetes Care 38:2009\u20132017","journal-title":"Diabetes Care"},{"key":"4370_CR58","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.2337\/dc13-0663","volume":"36","author":"E Ferrannini","year":"2013","unstructured":"Ferrannini E, Berk A, Hantel S et al (2013) Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care 36:4015\u20134021","journal-title":"Diabetes Care"},{"key":"4370_CR59","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.2337\/dc12-2673","volume":"36","author":"HU H\u00e4ring","year":"2013","unstructured":"H\u00e4ring HU, Merker L, Seewaldt-Becker E et al (2013) Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 36:3396\u20133404","journal-title":"Diabetes Care"},{"key":"4370_CR60","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","volume":"1","author":"M Roden","year":"2013","unstructured":"Roden M, Weng J, Eilbracht J et al (2013) Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 1:208\u2013219","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4370_CR61","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.2337\/dc13-2105","volume":"37","author":"HU H\u00e4ring","year":"2014","unstructured":"H\u00e4ring HU, Merker L, Seewaldt-Becker E et al (2014) Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 37:1650\u20131659","journal-title":"Diabetes Care"},{"key":"4370_CR62","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","volume":"2","author":"AH Barnett","year":"2014","unstructured":"Barnett AH, Mithal A, Manassie J et al (2014) Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2:369\u2013384","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4370_CR63","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(14)70120-2","volume":"2","author":"M Ridderstrale","year":"2014","unstructured":"Ridderstrale M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC (2014) Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2:691\u2013700","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4370_CR64","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/dom.12188","volume":"16","author":"CS Kovacs","year":"2014","unstructured":"Kovacs CS, Seshiah V, Swallow R et al (2014) Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 16:147\u2013158","journal-title":"Diabetes Obes Metab"},{"key":"4370_CR65","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.2337\/dc13-3055","volume":"37","author":"J Rosenstock","year":"2014","unstructured":"Rosenstock J, Jelaska A, Frappin G et al (2014) Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 37:1815\u20131823","journal-title":"Diabetes Care"},{"key":"4370_CR66","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/dom.12503","volume":"17","author":"J Rosenstock","year":"2015","unstructured":"Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, Woerle HJ (2015) Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 17:936\u2013948","journal-title":"Diabetes Obes Metab"},{"key":"4370_CR67","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s12325-015-0198-0","volume":"32","author":"T Kadowaki","year":"2015","unstructured":"Kadowaki T, Haneda M, Inagaki N et al (2015) Efficacy and safety of empagliflozin monotherapy for 52 weeks in Japanese patients with type 2 diabetes: a randomized, double-blind, parallel-group study. Adv Ther 32:306\u2013318","journal-title":"Adv Ther"},{"key":"4370_CR68","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/dom.12464","volume":"17","author":"E Araki","year":"2015","unstructured":"Araki E, Tanizawa Y, Tanaka Y et al (2015) Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab 17:665\u2013674","journal-title":"Diabetes Obes Metab"},{"key":"4370_CR69","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2337\/dc14-1096","volume":"38","author":"I Tikkanen","year":"2015","unstructured":"Tikkanen I, Narko K, Zeller C et al (2015) Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 38:420\u2013428","journal-title":"Diabetes Care"},{"key":"4370_CR70","doi-asserted-by":"crossref","first-page":"394","DOI":"10.2337\/dc14-2365","volume":"38","author":"A Lewin","year":"2015","unstructured":"Lewin A, DeFronzo RA, Patel S et al (2015) Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care 38:394\u2013402","journal-title":"Diabetes Care"},{"key":"4370_CR71","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/dc14-2364","volume":"38","author":"RA DeFronzo","year":"2015","unstructured":"DeFronzo RA, Lewin A, Patel S et al (2015) Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care 38:384\u2013393","journal-title":"Diabetes Care"},{"key":"4370_CR72","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2337\/dc16-0522","volume":"39","author":"S Hadjadj","year":"2016","unstructured":"Hadjadj S, Rosenstock J, Meinicke T, Woerle HJ, Broedl UC (2016) Initial combination of empagliflozin and metformin in patients with type 2 diabetes. Diabetes Care 39:1718\u20131728","journal-title":"Diabetes Care"},{"key":"4370_CR73","unstructured":"NCT01734785 (2016) Safety and efficacy of the combination of empagliflozin and linagliptin compared to linagliptin alone over 24 weeks in patients with type 2 diabetes. Available from \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT01734785\n\n. Accessed 15 July 2016"},{"key":"4370_CR74","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S2213-8587(16)00052-8","volume":"4","author":"JH Wu","year":"2016","unstructured":"Wu JH, Foote C, Blomster J et al (2016) Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 4:411\u2013419","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4370_CR75","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s13300-014-0053-3","volume":"5","author":"TP Reilly","year":"2014","unstructured":"Reilly TP, Graziano MJ, Janovitz EB et al (2014) Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus. Diabetes Ther 5:73\u201396","journal-title":"Diabetes Ther"},{"key":"4370_CR76","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/jcpt.12077","volume":"38","author":"S Cangoz","year":"2013","unstructured":"Cangoz S, Chang YY, Chempakaseril SJ et al (2013) The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors. J Clin Pharm Ther 38:350\u2013359","journal-title":"J Clin Pharm Ther"},{"key":"4370_CR77","doi-asserted-by":"crossref","first-page":"E4111","DOI":"10.1073\/pnas.1511698112","volume":"112","author":"C Scafoglio","year":"2015","unstructured":"Scafoglio C, Hirayama BA, Kepe V et al (2015) Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci U S A 112:E4111\u2013E4119","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4370_CR78","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrd3180","volume":"9","author":"EC Chao","year":"2010","unstructured":"Chao EC, Henry RR (2010) SGLT2 inhibition\u2014a novel strategy for diabetes treatment. Nat Rev Drug Discov 9:551\u2013559","journal-title":"Nat Rev Drug Discov"},{"key":"4370_CR79","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1507\/endocrj.EJ15-0396","volume":"62","author":"T Saito","year":"2015","unstructured":"Saito T, Okada S, Yamada E et al (2015) Effect of dapagliflozin on colon cancer cell [rapid communication]. Endocr J 62:1133\u20131137","journal-title":"Endocr J"},{"key":"4370_CR80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canep.2016.02.010","volume":"42","author":"J Wang","year":"2016","unstructured":"Wang J, Yang DL, Chen ZZ, Gou BF (2016) Associations of body mass index with cancer incidence among populations, genders, and menopausal status: a systematic review and meta-analysis. Cancer Epidemiol 42:1\u20138","journal-title":"Cancer Epidemiol"},{"key":"4370_CR81","doi-asserted-by":"crossref","first-page":"e0119313","DOI":"10.1371\/journal.pone.0119313","volume":"10","author":"JW Sun","year":"2015","unstructured":"Sun JW, Zhao LG, Yang Y, Ma X, Wang YY, Xiang YB (2015) Obesity and risk of bladder cancer: a dose-response meta-analysis of 15 cohort studies. PLoS One 10:e0119313","journal-title":"PLoS One"},{"key":"4370_CR82","doi-asserted-by":"crossref","first-page":"g5630","DOI":"10.1136\/bmj.g5630","volume":"349","author":"MA Puhan","year":"2014","unstructured":"Puhan MA, Schunemann HJ, Murad MH et al (2014) A GRADE working group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 349:g5630","journal-title":"BMJ"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-017-4370-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-017-4370-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-017-4370-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T07:40:34Z","timestamp":1504165234000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-017-4370-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,19]]},"references-count":82,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["4370"],"URL":"https:\/\/doi.org\/10.1007\/s00125-017-4370-8","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,19]]}}}